Business Context and Reporting Period
Company: Pliant Therapeutics, Inc. (PLRX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2025
Event: Termination of a Material Definitive Agreement (Item 1.02)
Key Financial Metrics
This filing reports a specific debt repayment event rather than comprehensive financial statements. Key figures include:
- Total Payoff Amount: $32.4 million (comprising all outstanding principal, accrued interest, fees, costs, and expenses).
- Original Loan Facility: Up to $150 million aggregate principal.
- Amount Borrowed: $30 million.
- Interest Rate Structure: Floating rate equal to the greater of 1-month SOFR or 3.5%, plus 5.25%, with a floor of 8.75%.
- Repayment Schedule: Originally scheduled to begin July 1, 2028, with consecutive equal monthly principal payments.
Material Changes
On October 14, 2025, the Company voluntarily prepaid the entire outstanding balance of its Amended and Restated Loan and Security Agreement dated March 11, 2024. This action resulted in the full satisfaction and discharge of all obligations, covenants, debts, and liabilities under the agreement. Consequently, the Loan Agreement and all related documents were terminated.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the context of the debt termination. The primary implication is the removal of the debt obligation and associated covenants from the Company's balance sheet as of the payoff date.
Investor Verification Checklist
- Verify the source of the $32.4 million used for the voluntary prepayment (e.g., cash on hand, new equity issuance, or other financing).
- Confirm the impact of this debt removal on the Company's current liquidity position and cash runway.
- Review subsequent filings for any new debt agreements or changes in capital structure following this termination.
- Check if the prepayment triggered any change in control provisions or other contractual obligations not mentioned in this 8-K.